1
|
Doroff CE, Langford EL, Ryan GA, Snarr RL. Effects of Active Sitting on Reading and Typing Task Productivity. INTERNATIONAL JOURNAL OF EXERCISE SCIENCE 2019; 12:1216-1224. [PMID: 31839855 PMCID: PMC6886608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Increased sedentary behavior and reduced physical activity among children and adults has led to the advent of various active devices to combat these behaviors. Active sitting, consisting of modified chairs or stability balls, allows the body to stay dynamic while seated. While research has evaluated the health benefits of active sitting, minimal research has shown the effects of active sitting on productivity in adult populations. The purpose was to evaluate the effects of various chairs (active versus non-active) on typing and reading task productivity. Twenty adult participants performed typing and reading tasks for 10-minutes while sitting on each of the following: standard chair (SC), stability ball (SB), and active sitting chair (ST). Reading comprehension (RC), words per minute (WPM), accuracy, and errors were measured following each task. Additionally, perceived productivity was measured using a self-reported rating of difficulty scale (1-10). In terms of RC, there was no difference between the chairs (p = 0.16). However, perceived productivity was significantly greater on the SC as compared to SB (p < 0.01) and ST (p < 0.01). For the typing task, no differences were demonstrated for errors (p = 0.87) or accuracy (p = 0.91). However, WPM was significantly greater on SC (38.8 ± 10.5) compared to ST (35.9 ± 9.5) (p = 0.02). For perceived typing productivity, SC and SB demonstrated significantly greater values compared to ST (p < 0.01). Results suggest that various types of active sitting may have a minimal negative effect on workplace performance and perceived productivity.
Collapse
Affiliation(s)
- Claire E Doroff
- Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, GA, USA
| | - Emily L Langford
- Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, GA, USA
- Department of Kinesiology and Health Promotion, University of Kentucky, Lexington, KY, USA
| | - Greg A Ryan
- Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, GA, USA
| | - Ronald L Snarr
- Department of Health Sciences and Kinesiology, Georgia Southern University, Statesboro, GA, USA
| |
Collapse
|
2
|
Tanaka Y, Kameda H, Saito K, Kaneko Y, Tanaka E, Yasuda S, Tamura N, Fujio K, Fujii T, Kojima T, Anzai T, Hamada C, Fujino Y, Matsuda S, Kohsaka H. Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. Arthritis Res Ther 2018; 20:151. [PMID: 30029613 PMCID: PMC6053758 DOI: 10.1186/s13075-018-1647-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 06/18/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Following the onset of rheumatoid arthritis (RA), patients experience a functional decline caused by various joint symptoms which affects their activities of daily living and can lead to reduced work productivity. We evaluated the effect of a 52-week treatment with tocilizumab by subcutaneous injection (TCZ-SC) among biologic-naive Japanese house workers (HWs) and paid workers (PWs) with RA in a real-world clinical practice. METHODS This multicenter, observational, prospective study enrolled 377 and 347 RA patients into TCZ-SC and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)-alone groups, respectively. The primary endpoint was the change in percentage of overall work impairment (OWI) among PWs at week 52 assessed using the Work Productivity and Activity Impairment Questionnaire (WPAI). Inverse probability of treatment weighting analyses were used to compare treatments. The Work Functioning Impairment Scale, disease activity, quality of life (QOL) measures, and safety were also assessed. RESULTS The weighted change in OWI from baseline for PWs was -18.9% (TCZ-SC group) and -19.0% (csDMARDs group) at week 52, without a significant between-group difference (adjusted treatment difference 0.1, 95% confidence interval (CI) -6.3 to 6.5; P = 0.978). Changes in WPAI activity impairment in the overall group (between-group difference -6.4, 95% CI -10.7 to -2.2; P = 0.003) and HWs (-9.5, 95% CI - 16.0 to -2.9; P = 0.005) were significantly better with TCZ-SC than with csDMARDs at week 52. TCZ-SC-treated HWs showed significant improvement in all QOL assessments (Frenchay Activities Index, EuroQol 5 Dimension (EQ-5D), Japanese Health Assessment Questionnaire Disability Index (HAQ-DI), and 6-item Kessler scale (K6)) at week 52; PWs did not show any between-group differences for these QOL measures. Disease activity (Disease Activity Score 28-erythrocyte sedimentation rate, Clinical Disease Activity Index, and Simplified Disease Activity Index) and QOL measures (EQ-5D, HAQ-DI, and K6) improved over time in the overall group. No new safety concerns were raised with TCZ-SC. CONCLUSIONS Despite the lack of differences in OWI between groups at week 52, the overall group (particularly HWs) receiving TCZ-SC in addition to csDMARDs showed significant improvements in activity impairment, disease activity, and QOL versus those receiving csDMARDs alone. This study may promote the evaluation of work productivity improvements in HWs and PWs by RA treatment.
Collapse
Affiliation(s)
- Yoshiya Tanaka
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan.
| | - Hideto Kameda
- Toho University, 2-22-36 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan
| | - Kazuyoshi Saito
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan.,Tobata General Hospital, 1-3-33 Fukuryugi, Tobata-ku, Kitakyushu, Fukuoka, 804-0025, Japan
| | - Yuko Kaneko
- Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Eiichi Tanaka
- Tokyo Women's Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo, 162-0054, Japan
| | - Shinsuke Yasuda
- Hokkaido University, N15, W7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Naoto Tamura
- Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
| | - Keishi Fujio
- The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan
| | - Takao Fujii
- Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan
| | - Toshihisa Kojima
- Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Tatsuhiko Anzai
- EPS Corporation, 6-29 Shinogawamachi, Shinjuku-ku, Tokyo, 162-0814, Japan
| | - Chikuma Hamada
- Tokyo University of Science, 6-3-1 Niijuku, Katsuhika-ku, Tokyo, 125-8585, Japan
| | - Yoshihisa Fujino
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan
| | - Shinya Matsuda
- University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, 807-0804, Japan
| | - Hitoshi Kohsaka
- Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| |
Collapse
|
3
|
Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. Adv Ther 2017; 34:686-702. [PMID: 28144917 PMCID: PMC5350205 DOI: 10.1007/s12325-017-0477-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Indexed: 02/03/2023]
Abstract
INTRODUCTION The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. METHODS Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness. RESULTS Of the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%. CONCLUSIONS Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA. FUNDING AbbVie GK and Eisai Co., Ltd. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT01346488.
Collapse
|
4
|
Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016; 36:685-95. [PMID: 26746843 PMCID: PMC4839053 DOI: 10.1007/s00296-015-3415-x] [Citation(s) in RCA: 181] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 12/23/2015] [Indexed: 12/19/2022]
Abstract
While rheumatologists often focus on treatment targets, for many patients with rheumatoid arthritis (RA), control over pain and fatigue, as well as sustaining physical function and quality of life (QoL), is of primary importance. This literature review aimed at examining patients' and physicians' treatment aspirations, and identifying the unmet needs for patients with RA receiving ongoing treatment. Searches were performed using MEDLINE, Embase, PsycINFO, and Econlit literature databases for articles published from 2004 to 2014 in the English language. Published literature was screened to identify articles reporting the unmet needs in RA. We found that, despite the wide range of available treatments, RA continues to pose a substantial humanistic and economic burden on patients, and there are still unmet needs across key domains such as pain, physical function, mental function, and fatigue. These findings suggest that there is a need for further treatment advances in RA that address these domains of contemporary unmet need.
Collapse
Affiliation(s)
- Peter C Taylor
- Rheumatology and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
| | - Adam Moore
- Endpoint Development and Outcomes Assessment, Adelphi Values, Cheshire, UK.,ICE Creates Ltd, Birkenhead, UK
| | | | - Jose Alvir
- Global Innovative Pharma Business, Pfizer Inc, New York, NY, USA
| | | |
Collapse
|
5
|
Engel-Nitz NM, Ogale S, Kulakodlu M. Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs. Rheumatol Ther 2015; 2:127-139. [PMID: 27747532 PMCID: PMC4883262 DOI: 10.1007/s40744-015-0015-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Indexed: 12/31/2022] Open
Abstract
INTRODUCTION This study examined the use of anti-tumor necrosis factor (anti-TNF) monotherapy, adherence with non-biologic disease-modifying anti-rheumatic drugs (nbDMARDs) in patients receiving a combination of anti-TNF therapies and nbDMARDs, and the impact of nbDMARD adherence on anti-TNF persistence among patients with rheumatoid arthritis (RA). METHODS Patients with RA (aged ≥18 years) from a US commercial health plan with claims for anti-TNFs (2006-2010) were defined as either biologic-naive or -exposed anti-TNF initiators based on previous nbDMARD use. Adherence to nbDMARDs and anti-TNF persistence were estimated. Cox regression estimated the association between nbDMARD adherence and anti-TNF persistence. RESULTS Among 9764 patients identified (mean age 50.2 years; 78% female), 55% of biologic-naive patients and 49% of previously exposed patients initiated any combination therapy during follow-up. Among biologic-naive combination therapy patients, 53% adhered to nbDMARD therapy <80% of the time while receiving anti-TNF therapies; 33% had <60% adherence. Compared with the most adherent patients, patients adherent to nbDMARDs 20% to 79% of the time were 30% to 20% more likely to discontinue their anti-TNF therapy in the period >90 days after starting the anti-TNF therapy. This relationship was not observed for patients with nbDMARD adherence of <20% (who were less likely to discontinue their anti-TNF therapy during the first 90 days of treatment). CONCLUSION Almost one-third of patients with RA receiving anti-TNF therapy received it as pure monotherapy. About one-third of combination therapy recipients had <60% adherence to nbDMARDs. Higher nbDMARD adherence may be associated with better anti-TNF persistence after an initial treatment period.
Collapse
|